Biosimilars in rheumatology: what the clinician should know

Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including equivalenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Castañeda-Hernández, Gilberto, González-Ramírez, Rodrigo, Kay, Jonathan, Scheinberg, Morton A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613175/
https://www.ncbi.nlm.nih.gov/pubmed/26509046
http://dx.doi.org/10.1136/rmdopen-2014-000010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613175/
https://www.ncbi.nlm.nih.gov/pubmed/26509046
http://dx.doi.org/10.1136/rmdopen-2014-000010

Ejemplares similares